Regulatory Approval Secured for European Market Entry

The European Commission (EC) has granted final marketing authorization for Pyzchiva, a ustekinumab biosimilar developed by Samsung Bioepis. This approval follows approximately two months after the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) issued a positive opinion. With the completion of rigorous scientific review by regulatory authorities, Pyzchiva is now eligible for legal distribution and prescription across all European Union (EU) member states. This achievement demonstrates Samsung Bioepis's ability to develop and supply high-quality bio-pharmaceuticals in a timely manner, further solidifying its position in the global market.

Mechanism of Action and Clinical Significance of Interleukin Inhibitors

Pyzchiva uniquely inhibits interleukin-12 (IL-12) and interleukin-23 (IL-23), which are signaling molecules that mediate immune responses. By targeting and controlling these abnormally activated immune proteins in patients with autoimmune diseases, Pyzchiva effectively reduces inflammation and improves symptoms. Clinical trials have demonstrated that Pyzchiva exhibits comparable safety and efficacy to the originator product, providing reassurance to both patients and healthcare professionals. It offers a new treatment option for patients with moderate-to-severe plaque psoriasis, Crohn's disease, and ulcerative colitis who have not responded to existing therapies, highlighting its significant clinical value.

Strategic Partnership with Sandoz to Facilitate Distribution

To ensure the successful market launch of Pyzchiva, Samsung Bioepis has partnered with Sandoz, a global leader in generic and biosimilar pharmaceuticals. The two companies signed a commercialization partnership agreement in September 2023, granting Sandoz marketing and distribution rights in Europe, as well as key markets such as the United States and Canada. Sandoz's extensive sales network and proven marketing expertise are expected to significantly contribute to overcoming initial market entry barriers for Pyzchiva. Given that the success of the biosimilar market hinges on the speed of initial market share acquisition, this joint strategy with a major distributor is considered a shrewd business model.

Fierce Competition in the $10 Billion Market

The originator product of Pyzchiva, Stelara, is a blockbuster drug with global sales of approximately $10.9 billion in 2023. Due to this substantial market size, several biotechnology companies have been competing to develop biosimilars in anticipation of patent expiration. In the European market, Uzpruvo, co-developed by Alvotech and Teva, has already obtained marketing authorization, making a fierce competition for market share inevitable. To overcome the disadvantages of being a late entrant, Samsung Bioepis is expected to focus on securing price competitiveness through cost reduction and actively participating in tenders.

Benefits of Reducing Healthcare Costs and Improving Patient Access

The introduction of biosimilars plays a crucial role in alleviating the enormous burden on national healthcare budgets and improving patient access to expensive therapies. The availability of Pyzchiva at a relatively lower price compared to the originator product can directly contribute to improving the financial stability of governments and insurance companies. Several European countries are actively promoting the prescription of biosimilars, indicating a positive outlook for market expansion. As the prescription of Pyzchiva gradually increases, more patients with autoimmune diseases will be able to benefit from advanced biological therapies without facing financial barriers.